Patents by Inventor Sergey Menis

Sergey Menis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOGENIC TRIMERS
    Publication number: 20230016284
    Abstract: The invention relates to PGT121-germline-targeting designs, trimer stabilization designs, combinations of those two, trimers designed with modified surfaces helpful for immunization regimens, other trimer modifications and on development of trimer nanoparticles and methods of making and using the same.
    Type: Application
    Filed: August 11, 2021
    Publication date: January 19, 2023
    Inventors: Jon Steichen, Dan Kulp, Xiaozhen Hu, Sergey Menis, William Schief, Sebastian Raemisch
  • Engineered outer domain (eOD) of HIV GP120, mutants and use thereof
    Patent number: 11248027
    Abstract: The present invention relates to engineered outer domain (eOD) immunogens of HIV gp120 and mutants thereof and methods of making and using the same. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity. The mutant eODs bind to neutralizing antibody precursors. The mutant eODs can activate germline precursors on the pathway to eliciting a broadly neutralizing antibody (bnAb) response. The invention also relates to immunized knock-in mice expressing germline-reverted heavy chains. Induced antibodies showed characteristics of bnAbs and mutations that favored binding to near-native HIV-1 gp120 constructs. In contrast, native-like immunogens failed to activate precursors. The invention also relates to rational epitope design that can prime rare B cell precursors for affinity maturation to desired targets.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: February 15, 2022
    Assignees: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: William Schief, Sergey Menis, Daniel Kulp, Joseph Jardine
  • Immunogenic trimers
    Patent number: 11203617
    Abstract: The invention relates to PGT121-germline-targeting designs, trimer stabilization designs, combinations of those two, trimers designed with modified surfaces helpful for immunization regimens, other trimer modifications and on development of trimer nanoparticles and methods of making and using the same.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: December 21, 2021
    Assignees: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Jon Steichen, Dan Kulp, Xiaozhen Hu, Sergey Menis, William Schief, Sebastian Raemisch
  • FERRITIN NANOPARTICLE DISPLAYING AN HIV TRIMER
    Publication number: 20210363194
    Abstract: The present invention relates to glycosylate HIV timer nanoparticles fused to self-assembling ferritin proteins which may be utilized as immunogens to enhance trafficking to lymph nodes and germinal centers and to heighten immune responses.
    Type: Application
    Filed: June 5, 2019
    Publication date: November 25, 2021
    Inventors: Talar Tokatlian, Benjamin J. Read, Daniel W. Kulp, Sergey Menis, Jon M. Steichen, William R. Schief, Darrell J. Irvine
  • IMMUNOGENIC TRIMERS
    Publication number: 20190085033
    Abstract: The invention relates to PGT121-germline-targeting designs, trimer stabilization designs, combinations of those two, trimers designed with modified surfaces helpful for immunization regimens, other trimer modifications and on development of trimer nanoparticles and methods of making and using the same.
    Type: Application
    Filed: September 24, 2018
    Publication date: March 21, 2019
    Inventors: Jon Steichen, Dan Kulp, Xiaozhen Hu, Sergey Menis, William Schief, Sebastian Raemisch
  • ENGINEERED OUTER DOMAIN (EOD) OF HIV GP120, MUTANTS AND USE THEREOF
    Publication number: 20180194809
    Abstract: The present invention relates to engineered outer domain (eOD) immunogens of HIV gp120 and mutants thereof and methods of making and using the same. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity. The mutant eODs bind to neutralizing antibody precursors. The mutant eODs can activate germline precursors on the pathway to eliciting a broadly neutralizing antibody (bnAb) response. The invention also relates to immunized knock-in mice expressing germline-reverted heavy chains. Induced antibodies showed characteristics of bnAbs and mutations that favored binding to near-native HIV-1 gp120 constructs. In contrast, native-like immunogens failed to activate precursors. The invention also relates to rational epitope design that can prime rare B cell precursors for affinity maturation to desired targets.
    Type: Application
    Filed: December 18, 2017
    Publication date: July 12, 2018
    Inventors: William Schief, Sergey Menis, Daniel Kulp, Joseph Jardine